TORG
Cryptocurrencies seem to be the flavour of the season as increasingly more people around the world are embracing them; sometimes even abandoning their traditional avenues like Equity, Gold, etc. Though the concept of crypto (as they are informally called) investment seems novel, the first cryptocurrency came into the market more than a decade back. The reliable supply, decentralised control, swift success, and exorbitant returns given by cryptocurrencies have now allayed all fears of them being a ‘fad’ or even a ‘sham’. Today, you have many different options of cryptocurrencies trading on different real-time online platforms.
Though, as the cryptocurrencies do not have any underlying asset to base your buying or selling decision upon (for example – Google shares move on the performance of the Google companies), all the cryptocurrencies on the face look similar. But, one cryptocurrency, recently launched, is destined to change all that, and is already making waves around the world as people are lapping it up in droves.
TORG is the world’s first sustainability driven, completely decentralized, and utility-focused cryptocurrency, aimed at global human development. If it sounds confusing, it’s because it’s such a new concept. As the world’s first utilimeme, it combines the power of meme-driven popularity with the sustainability that comes with a focus on global utility.
Launched recently on 20th July 2021, TORG has already reached the maximum supply of 777 billion and its current circulating supply is 100%. TORG is secured as an ERC-20 token on the Ethereum blockchain. It is not open to pausing, minting, and mining. Being extremely secure and stable, TORG’s smart contract is audited by the best in the industry blockchain security and infrastructure leader Certik.
TORG started trading from 20th July 2021 on world’s leading Global Exchanges, namely Uniswap , BitMart , CoinTiger , ProBit , CoinsBit Global , CoinsBit India , WhiteBit , HotBit.io , LA Token , IndoEx International , Bilaxy , etc. It is expanding its reach rapidly and is expected to be available on many trading platforms, big & small, shortly. Since the launch, different pairs of TORG have been added by the centralized exchanges, including TORG/USDT, TORG/BTC, and TORG/ETH .
TORG – It is different, but is it better?
What makes TORG better than other cryptocurrencies is the same thing that makes the world a better place to live in, i.e. focus on sustainability. TORG is not just any regular cryptocurrency. It is the world’s first cryptocurrency that has sustainability & utility as its underlying core assets. It aims to increase commercial & business activities, generate growth & employment opportunities for the world’s youth, develop eco-friendly infrastructure around the world, push the population to adopt green initiatives, and alleviate the economic constraints facing the world’s marginalized demographic sections.
About TORG
TORG Foundation is the force behind this intuitive & innovative cryptocurrency that aims to disrupt the crypto market forever. With the mission & vision of helping the society keep its carbon footprint to the minimum while increasing the economic activities both in developing & developed countries for the holistic development of mankind, the foundation keeps the interests of humanity and mankind at the core of all its decisions.
To maintain the full transparency of transactions, TORG is completely decentralised, and the foundation does not & cannot decide or predict its price movements.
It’s #TORGTime.
For more information and updates, visit www.torg.to or follow TORG on Twitter , Telegram , Facebook , and Medium .
Disclaimer: The information available on this article is for educational purposes only and not an offer, solicitation of an offer, or advice to buy or sell securities, investment or tax advice. Purchasing cryptocurrencies comes with a number of risks. All Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the statements made here. The data and non-TORG names are for informational and identification purposes only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005103/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1GLOBAL Empowers Revolut to Offer Mobile Plans in Poland16.12.2025 13:04:00 CET | Press release
1GLOBAL, a technology-driven global mobile communications provider, strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216769985/en/ 1GLOBAL strengthens its partnership with Revolut, expanding the leading neobank’s mobile data plan offering to the Polish market. By integrating 1GLOBAL’s eSIM capability into its multi-service app, Revolut’s customers in Poland who signed up to the waitlist can now enjoy bundled mobile plans that include competitively priced domestic data plans starting at zł 25 per month (approx. €6.00 per month) with unlimited calls and texts in Poland and the EU, in just a few taps. For 1GLOBAL, this expansion marks another milestone in the company’s embedded telco services strategy. The services are trusted by more than 4,000 corporate partners across a variety of industries including fi
Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release
Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment
Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release
With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release
PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom